Imaging agent for breast cancer PET gets FDA nod

Siemens Healthineers subsidiary PETNet Solutions and Zionexa have announced...Read more on AuntMinnie.comRelated Reading: ASTRO: Radiation therapy slashes breast cancer recurrence MRI + mammography detects recurrent breast cancer Blue Earth, PETNet expand Axumin distribution SNMMI: FDG-PET predicts breast cancer outcomes Blue Earth, PETNet roll out Axumin
Source: Headlines - Category: Radiology Source Type: news

Related Links:

Liz Satterfield has a ritual for every time she returns home after leaving the house. Diagnosed with metastatic breast cancer in 2016, the Kirkland, Washington resident recently learned that the cancer that had spread to her brain in 2018 was still growing. Throughout the pandemic, she’s had to visit the hospital at least once every three weeks, often more frequently, for treatments to control her disease. “I have a pair of shoes in a paper bag that I keep in the trunk of my car or a rack in the garage. I only wear those shoes when I’m going in to get treatment,” she says. “When I come home, I...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 Source Type: news
A previously healthy 36-year-old premenopausal woman with no known family history of breast cancer presented with palpable nodules in her left breast. Diagnostic mammogram and ultrasound demonstrated an 8 × 4 cm area of segmental pleomorphic calcifications with scattered masses in the left breast at 7 to 8 o’clock. A biopsy of the anterior and posterior left breast lesions showed an invasive ductal carcinoma. Intermediate nuclear grade estrogen and progesterone receptors stained positive (>90%), and human epidermal growth factor receptor 2 (HER2) was equivocal by fluorescence in situ hybridization.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Source Type: research
This study included 516 women who underwent CESM imaging for screening and diagnostic purposes between 2012 and 2015 in a single center. BPE at CESM images was retrospectively, independently and blindly graded by six experienced radiologists using the following scale: minimal, mild, moderate, or marked. Agreement between readers was estimated using Kendall's W coefficient of concordance. Associations between clinical factors and BPE, and between BPE and breast cancer were examined using generalized estimating equations. Association between BPE and breast cancer was assessed for the whole study group, and for the screening ...
Source: Academic Radiology - Category: Radiology Source Type: research
This study evaluated compliance and implementation of these recommendations.MethodsA database of patients undergoing breast cancer surgery was retrospectively queried from 2002-2017. Patients were divided into cohorts before and after the year of each guideline publication.ResultsThe rate of presentation on mammography was not different before 2009 (65%) vs. after 2009 (66%). RT was given to 57% of patients with T1 ER+Her2- prior to 2013 vs. 27% after (p=
Source: The American Journal of Surgery - Category: Surgery Source Type: research
ConclusionThe results showed lower incremental costs of DBT vs. DM, compared to what is found in previous cost analyses of DBT and DM. However, the incremental costs were still higher for DBT compared with DM after including recall costs. Further studies with long-term treatment data are needed to understand the complete costs of implementing DBT in screening.
Source: The European Journal of Health Economics - Category: Health Management Source Type: research
Worldwide breast cancer is the leading type of cancer in women [1]. However, 99 percent of women whose breast cancer was detected early (stage 1 or 0) survive beyond five years after diagnosis [2]. Indeed, when detected in good time, its treatment allows women to have a good prognosis reducing the rate of mortality and the incidence of surgery, radiation therapy and oncologic treatments [3]. Mammography is the most widely used technique in screening programs to detect breast cancer at a very early stage [4,5], but it is not a perfect procedure.
Source: Physica Medica: European Journal of Medical Physics - Category: General Medicine Authors: Tags: Original paper Source Type: research
ConclusionPLM plays an important role in the evaluation of patients undergoing breast conservation for breast cancer presenting with microcalcifications. Residual malignancy was detected on positive PLM in 6% of patients with negative margins.
Source: Breast Cancer Research and Treatment - Category: Cancer & Oncology Source Type: research
Conclusion: 18F-FDG PET/CT revealed previously unsuspected distant metastases in 16% of male patients with pre-PET/CT stage IIB breast cancer and 33% of those with stage III breast cancer. These rates are comparable to previously published upstaging rates in female patients. 18F-FDG PET/CT demonstrates value for systemic staging of male patients with breast cancer and should be considered for use in newly diagnosed patients, particularly those with stage IIB and III disease.
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Clinical Source Type: research
Normally, when a physician notices a suspicious mass or lesion on a mammogram, he or she will request an ultrasound to explore it further. Based on those results, a biopsy may be performed to determine whether the mass is cancerous. “Unfortunately, right now, in some cases, physicians either overdiagnose or underdiagnose based on that biopsy, because with ultrasound they can only see so much,” said Lori Chmura, CEO of Dune Medical Devices. “The doctor is essentially going in blindly, trying to see what looks like the most suspicious area, and they’re t...
Source: MDDI - Category: Medical Devices Authors: Tags: Business Source Type: news
Authors: Jaiswal K, Hull M, Furniss AL, Doyle R, Gayou N, Bayliss E Abstract Background: Timely detection and treatment of breast cancer is important in optimizing survival and minimizing recurrence. Given disparities in breast cancer outcomes based on socioeconomic status, we examined time to diagnosis and treatment in a safety-net hospital. Methods: We conducted a retrospective review of all patients with breast cancer diagnosed between July 1, 2010, and June 30, 2012 (N=120). We limited our analytic sample to patients with nonrecurrent, primary stage 0-III breast cancer (N=105) and determined intervals from pres...
Source: Journal of the National Comprehensive Cancer Network : JNCCN - Category: Cancer & Oncology Tags: J Natl Compr Canc Netw Source Type: research
More News: Breast Cancer | Cancer | Cancer & Oncology | Mammography | Radiation Therapy | Radiology